source
- FDA drafts guidance to speed approvals of individualized gene therapies, hailed as win for rare disease patientsThe U.S. Food and Drug Administration released draft guidance aimed at streamlining the approval process for certain individualized gene therapies. The proposal would allow sponsors to avoid filing…
- Biogen posts third consecutive quarter of revenue growth, driven by Leqembi, Spinraza and Apellis productsBiogen reported $2.8 billion in revenue for the third quarter, marking its third straight period of top‑line growth. The company credited its growth portfolio, led by the Alzheimer’s therapy Leqem…